Clinical Pharmacokinetics of Selected Psychotropic Drugs

  • D. R. Britton
  • Z. S. El-Wardany
  • C. P. Brown
  • J. R. Bianchine


The study of pharmacokinetics is intended to provide information about the dynamics of the various factors which determine the proportion of a given dose of a drug which will become available at specific receptor sites to produce a therapeutic or a toxic effect. In a generalized overview of the subject, Levine (1973) notes that these factors include (1) the rate and extent of absorption from the site of application; (2) the rate and extent of distribution to various tissues and fluids; (3) the rate of biotransformation to active or inactive metabolites; and (4) the rate of excretion from the body. These processes are a function of the physiochemical properties of the drug (e.g., lipid solubility and molecular weight) and of the physiologic status of the patient. As will be seen, this latter aspect is determined not only by intervening pathologic processes, but also to a great extent by normal interindividual variability in parameters such as the proportion of drug bound to plasma proteins, the rate of hepatic blood flow, and the activity of enzymatic processes responsible for biotransformation.


Plasma Level Renal Clearance Psychotropic Drug Lithium Treatment Lithium Concentration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adamson, L., Curry, S. H., Bridges, R. K., Firestone, A. F., Lavin, N. I., Lewis, D. M., Watson, R. D., Xaver, C. M., and Anderson, J. A., 1973, Fluphenazine decanoate trial in chronic in-patient schizophrenics failing to absorb oral CPZ, Dis. Nerv. Syst.24:181–191.Google Scholar
  2. Alexanderson, B., 1972, Pharmacokinetics of nortriptyline in man after single and multiple oral doses. The predictability of steady state plasma concentrations from single dose plasma level data, Eur. J. Clin. Pharmacol.4:196–200.Google Scholar
  3. Alexanderson, B., and Borgå, O., 1973, Urinary excretion of nortriptyline and five of its metabolites in man after single and multiple oral doses, Eur. J. Clin. Pharmacol.5:174–180.Google Scholar
  4. Alexanderson, B., Evans, D. A. P., and Sjoqvist, F., 1969, Steady state plasma levels of nortriptyline in twins: Influence of genetic factors and drug therapy, Br. Med. J.4:764–768.PubMedGoogle Scholar
  5. Alexanderson, B., Borgå, O., and Alvan, G., 1973, The availability of orally administered nortriptyline, Eur. J. Clin. Pharmacol.5:181–185.Google Scholar
  6. Almy, L. G. L., and Taylor, M. A., 1973, Lithium retention in mania, Arch. Gen. Psychiatry29:232–234.PubMedGoogle Scholar
  7. Anggard, E., Gunne, L.-M., Jonsson, L. E., and Niklasson, F., 1970, Pharmacokinetics and clinical studies on amphetamine dependent subjects, Eur. J. Clin. Pharmacol.3:3–11.Google Scholar
  8. Anggard, E., Jonsson, L., Hogmark, A., and Gunne, L., 1973, Amphetamine metabolism in amphetamine psychosis, Clin. Pharmacol. Ther.14:870–880.PubMedGoogle Scholar
  9. Åsberg, M., Cronholm, B., Sjoqvist, F., and Tuck, D., 1971, Relationship between plasma level and therapeutic effect of nortriptyline, Br. Med. J.3:331–334.PubMedGoogle Scholar
  10. Axelrod, J., 1954, Studies on sympathomimetic amines. II. The biotransformation and physiological disposition of d-amphetamine, d-p-hydroxyamphetamine and d-metham-phetamine, J. Pharmacol. Exp. Ther.110:315–326.PubMedGoogle Scholar
  11. Beckett, A. H., Salmon, J. A., and Mitchard, M., 1969, The relation between blood levels and urinary excretion of amphetamine under controlled acidic and under fluctuating urinary pH values using [14C]amphetamine, J. Pharm. Pharmacol.21:251–258.PubMedGoogle Scholar
  12. Bergner, P.-E. E., Bernikerk, K., Cooper, T. B., Gradigan, J. R., and Simpson, G. M., 1973, Lithium kinetics in man: Effect of variation in dosage pattern, Br. J. Pharmacol.49:328–339.PubMedGoogle Scholar
  13. Bickel, M. H., 1974, Binding of phenothiazines and related compounds to tissues and cell constituents, in: The Phenothiazines and Structurally Related Drugs (I. S. Forrest, C. J. Carr, and E. Usdin, eds.), pp. 163–166, Raven Press, New York.Google Scholar
  14. Bickel, M. H., and Weder, H. J., 1968, The total fate of a drug: Kinetics of distribution, excretion and formation of 14 metabolites in rats treated with imipramine, Arch. Int. Pharmacodyn. Ther.173:433–463.PubMedGoogle Scholar
  15. Biggs, J. T., Holland, W. H., and Sherman, W. R., 1975, Steady-state protriptyline levels in an out-patient population, Am. J. Psychiatry132:960–962.PubMedGoogle Scholar
  16. Birch, N. J., and Hullin, R. P., 1972, The distribution and binding of lithium following its long-term administration, Life Sci. (II)11:1095–1099.Google Scholar
  17. Birch, N. J., and Jenner, F. A., 1973, The distribution of lithium and its effects on the distribution and excretion of other ions in the rat, Br. J. Pharmacol.47:586–594.PubMedGoogle Scholar
  18. Bond, P. A., Brooks, B. A., and Judd, A., 1975, The distribution of lithium, sodium and magnesium in rat brain and plasma after various periods of administration of lithium in the diet, Br. J. Pharmacol.53:235–239.PubMedGoogle Scholar
  19. Borgå, O., Azarnoff, D. L., Forshell, G. P., and Sjoqvist, F., 1969, Plasma protein binding of tricyclic antidepressants in man, Biochem. Pharmacol.18:2135–2143.PubMedGoogle Scholar
  20. Byck, R., 1975, Drugs and the treatment of psychiatric disorders, in: The Pharmacological Basis of Therapeutics, 5th ed. (L. S. Goodman and A. Gilman, eds.), pp. 152–200, MacMillan, New York.Google Scholar
  21. Cade, J. F. J., 1949, Lithium salts in the treatment of psychotic excitement, Med. J. Aust.36:349–352.Google Scholar
  22. Caldwell, J., and Severs, P. S., 1974, The biochemical pharmacology of abused drugs. I. Amphetamines, cocaine and LSD, Clin. Pharmacol. Ther.16:625–638.PubMedGoogle Scholar
  23. Caldwell, J., Dring, L. G., and Williams, R. T., 1972, Norephedrines as metabolites of [14C]amphetamine in urine in man, Biochem. J.129:23–24.PubMedGoogle Scholar
  24. Carlson, A., Corrodi, H., Fuxe, K., and Hökfelt, T., 1969, Effects of some antidepressant drugs on the depletion of intraneuronal brain catecholamine stores caused by 4,α-dimethyl-meta-tyramine, Eur. J. Pharmacol.5:367–373.Google Scholar
  25. Chan, T. L., Sakalis, G., and Gershon, S., 1974, Quantitation of chlorpromazine and its metabolites in human plasma and urine by direct spectro-densitometry of thin layer chromatographs, in: The Phenothiazines and Structurally Related Drugs (I. S. Forrest, C. J. Carr, and E. Usdin, eds.), pp. 323–333, Raven Press, New York.Google Scholar
  26. Christiansen, J., and Gram, L. F., 1973, Imipramine and its metabolites in human brain, J. Pharm. Pharmacol.25:604–608.Google Scholar
  27. Cooper, T. B., Bergner, P. E., and Simpson, G. M., 1973, The 24 hour lithium level as a prognosticator of dosage requirements, Am. J. Psychiatry130:601–603.PubMedGoogle Scholar
  28. Cramer, J. K., Scott, B., Woods, H., and Rolfe, B., 1968, Metabolism of 14C-imipramine. 1. Excretion in the rat and in man, Psychopharmacologia12:263–277.Google Scholar
  29. Curry, S. H., 1970, Plasma protein binding of chlorpromaine, J. Pharm. Pharmacol.22:193–197.PubMedGoogle Scholar
  30. Curry, S. H., 1973, Action and metabolism of chlorpromazine, in: Biological Effects of Drugs in Relation to Their Plasma Concentrations (D. S. Davies and B. N. C. Prichard, eds.), pp. 201–210, University Park Press, Baltimore.Google Scholar
  31. Curry, S. H., and Mould, G. P., 1975, A microsomal oxidase system in rat intestinal mucosa, Br. J. Pharmacol.54:229P-230P.PubMedGoogle Scholar
  32. Curry, S. H., Davis, J. M., Janowsky, D. S., and Marshall, J. H. L., 1970, Factors affecting chlorpromazine plasma levels in psychiatric patients, Arch. Gen. Psychiatry22:209–215.PubMedGoogle Scholar
  33. Curry, S. H., DjMello, A., and Mould, G. P., 1971, Destruction of chlorpromazine during absorption in the rat in vivo and in vitro, Br. J. Pharmacol.42:403–411.PubMedGoogle Scholar
  34. Dasberg, H. H., van der Kleijn, E., Guelen, P. J. R., and van Praag, H. M., 1974, Plasma concentrations of diazepam and its metabolite n-methyldiazepam in relation to anxiolytic effect, Clin. Pharmacol. Ther.15:473–483.PubMedGoogle Scholar
  35. Demers, R. G., and Harris, R. L., 1972, The effect of dietary sodium on renal lithium excretion in the manic-depressive, Dis. Nerv. Syst.33:372–375.PubMedGoogle Scholar
  36. de Silva, J. A. F., Koechlin, B. A., and Bader, G., 1966, Blood level distribution patterns of diazepam and its major metabolite in man, J. Pharm. Sci.55:692–702.PubMedGoogle Scholar
  37. Dring, L. G., Smith, R. L., and Williams, R. T., 1970, The metabolic fate of amphetamine in man and other species, Biochem. J.116:425–435.PubMedGoogle Scholar
  38. Ebadi, M. S., Simmons, V.J., Hendrickson, M. J., and Lacy, P. S., 1974, Pharmacokinetics of lithium and its regional distribution in rat brain, Eur. J. Pharmacol.27:234–329.Google Scholar
  39. Ebert, M. H., Van Kammen, D. P., and Murphy, D. L., 1976, Plasma levels of amphetamine and behavioral response, in: Pharmacokinetics of Psychoactive Drugs (Gottschalk and Merlis, eds.), pp. 157–169, Spectrum Publications, New York.Google Scholar
  40. Elizur, A., Shopsin, B., Gershon, S., and Ehlenberger, A., 1972, Intracellular lithium ratios and clinical course in affective states, Clin. Pharmacol. Ther.13:947–953.PubMedGoogle Scholar
  41. Fann, W. E., Davis, J. M., Janowsky, D. S., Sekerke, H. J., and Schmidt, D. M., 1973, Chlorpromazine: Effects of antacids on its gastrointestinal absorption, J. Clin. Pharm.13:388–390.Google Scholar
  42. Forrest, F. M., Forrest, I. S., and Roisin, L., 1963, Clinical, biochemical and post mortem studies on a patient treated with CPZ, Aggressologie4:259–265.Google Scholar
  43. Forrest, I. S., and Green, D. E., 1972, Phenothiazines: Metabolism and analytical detection, J. Forensic Sci.17:592–617.PubMedGoogle Scholar
  44. Forrest, I. S., Forrest, F. M., Bolt, A. G., and Serra, M. T., 1967, An attempt to correlate urinary chlorpromazine excretion with clinical response to drug therapy, in: Proceedings of the Fifth International Congress of Neuro-Psychopharmacology, p. 1186, Exerpta Medicae, Amsterdam.Google Scholar
  45. Forrest, I. S., Bolt, A. G., and Serra, M. T., 1968, Distribution of chlorpromazine metabolites in selected organs of psychiatric patients chronically dosed up to the time of death, Biochem. Pharmacol.17:2061–2070.PubMedGoogle Scholar
  46. Forrest, I. S., Green, D. E., Melikian, A. P., and Serra, M. T., 1974, Total excretion of 3H-CPZ and 3H-prochlorperazine in chronically dosed animals: A balance sheet, in: The Phenothiazines and Structurally Related Drugs (J. S. Forrest, C. J. Carr, and E. Usdin, eds.), pp. 317–356, Raven Press, New York.Google Scholar
  47. Freychuss, U., Sjoqvist, F., and Tuck, D., 1970, Tyramine pressor effects in man before and during treatment with nortriptyline or ECT. Correlation between pharmacokinetics and effects of nortriptyline, Eur. J. Clin. Pharmacol.2:72–78.Google Scholar
  48. Fyro, B., Petterson, U., and Sedvall, G., 1973, Pharmacokinetics of lithium in manic-depressive patients, Acta Psychiatr. Scand.49:237–247.PubMedGoogle Scholar
  49. Gamble, J. A. S., MacKay, J. S., and Dundee, J. W., 1973, Plasma levels of diazepam, Br. J. Anaesth.45:1085.PubMedGoogle Scholar
  50. Garattini, S., Marcucci, F., Morselli, P. L., and Mussini, E., 1973, The significance of measuring blood levels of benzodiazepines, in: Biological Effects of Drugs in Relation to Their Plasma Concentrations, pp. 211–225, University Park Press, Baltimore.Google Scholar
  51. Glassman, A. H., Hurwich, M. J., and Perel, J. M., 1973, Plasma binding of imipramine and clinical outcome, Am. f. Psychiatry130:1367–1369.Google Scholar
  52. Glassman, A. H., Hurwic, M. J., Kanzler, M., Shostak, M., and Perel, J. M., 1974, Imipramine steady state studies and plasma binding, in: The Phenothiazines and Structurally Related Drugs (I. S. Forrest, C. J. Carr, and E. Usdin, eds.), pp. 457–461, Raven Press, New York.Google Scholar
  53. Glowinski, J., and Axelrod, J., 1964, Inhibition of uptake of tritiated noradrenaline in the intact rat brain by imipramine and structurally related compounds, Nature (London) 204:1318–1319.Google Scholar
  54. Glowinski, J., and Axelrod, J., 1966, Effects of drugs on the disposition of H3-norepinephrine in the rat brain, Pharmacol. Rev.18:775.PubMedGoogle Scholar
  55. Gottschalk, L. A., and Kaplan, S. A., 1972, Chlordiazepoxide plasma levels and clinical response, Comp. Psychiatry13:519–527.Google Scholar
  56. Gottschalk, L. A., Biener, R., and Dinovo, E. C., 1974, Effect of oral and intramuscular routes of administration on serum chlordiazepoxide levels and the prediction of these levels from predrug fasting serum glucose concentrations, Res. Commun. Chem. Pathol. Pharmacol.8:697–702.PubMedGoogle Scholar
  57. Gram, L. F., 1974, Metabolism of tricyclic antidepressants: A review, Dan. Med. Bull.21:218–232.PubMedGoogle Scholar
  58. Gram, L. F., and Christiansen, J., 1975, First pass metabolism of imipramine in man, Clin. Pharmacol. Ther.17:555–563.PubMedGoogle Scholar
  59. Gram, L. F., and Over, K. F., 1975, First pass metabolism of nortriptyline in man, Clin. Pharmacol. Ther.18:305–314.PubMedGoogle Scholar
  60. Greenblatt, D. J., and Koch-Weser, J., 1975, Clinical pharmacokinetics, N. Engl. J. Med.293:702–705, 964–970.Google Scholar
  61. Greenblatt, D. J., Shader, R. I., and Koch-Weser, J., 1974, Slow absorption of intramuscular chlordiazepoxide, N. Engl. J. Med.291:116–118.Google Scholar
  62. Greenblatt, D. J., Shader, R. I., and Koch-Weser, J., 1976, Clinical pharmacokinetics of chlordiazepoxide, in: Pharmacokinetics of Psychoactive Drugs (L. A. Gottschalk and S. Merlis, eds.), pp. 127–140, Spectrum Publications, New York.Google Scholar
  63. Gunne, L. M., and Anggard, E., 1974, Pharmacokinetic studies with amphetamines: Relationship to neuropsychiatric disorders, in: Pharmacology and Pharmacokinetics, Fo-garty International Center Proceedings, No. 20, Plenum Press, New York.Google Scholar
  64. Hammer, W., and Sjoqvist, F., 1967, Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds, Life Sci.6:1895–1903.PubMedGoogle Scholar
  65. Hillestad, L., Hansen, T., Melsom, H., and Drivines, A., 1974a, Diazepam metabolism in normal man. I. Serum concentrations and clinical effects after intravenous, intramuscular and oral administration, Clin. Pharmacol. Ther.16:479–484.PubMedGoogle Scholar
  66. Hillestad, L., Hansen, T., and Melsom, H., 19746, Diazepam metabolism in normal man. II. Serum concentrations and clinical effects after oral administration and cumulation, Clin. Pharmacol. Ther.16:485–489.Google Scholar
  67. Hollister, L. E., Curry, S. H., Derr, J. E., and Kanter, S. L., 1970, Studies of delayed action medication. V. Plasma levels and urinary excretion of four different dosage forms of chlorpromazine, Clin. Pharmacol. Ther.11:49–59.PubMedGoogle Scholar
  68. Hullin, R. P., McDonald, R., and Allsopp, M. N. E., 1975, Further reports on prophylactic lithium in recurrent affective disorders, Br. J. Psychiatry126:281–284.PubMedGoogle Scholar
  69. Jahnchen, E., Groth, U., and Prellwitz, W., 1974, Kinetics of salivary and urinary excretion of lithium in man after single oral doses, Naunyn-Schmiedebergs Arch. Pharmakol. 282(Suppl. R):39.Google Scholar
  70. Junod, A. F., 1972, Accumulation of 14C-imipramine in isolated perfused rat lungs, J. Pharmacol. Exp. Ther.183:182–187.PubMedGoogle Scholar
  71. Kanto, J., Iisalo, E., Lehtinen, V., and Salminen, J., 1974, The concentrations of diazepam and its metabolites in the plasma after an acute and chronic administration, Psychopharmacologia36:123–131.PubMedGoogle Scholar
  72. Kaul, P. N., Ticku, M. K., and Clark, M. L., 1972, Chlorpromazine metabolism. V. Disposition of free and conjugated metabolites in blood fractions of schizophrenic patients, J. Pharm. Sci.61:1753–1757.PubMedGoogle Scholar
  73. Kent, N. L., and McCance, R. A., 1974, The absorption and excretion of minor elements in man, Biochem. J.35:837.Google Scholar
  74. Koechlin, B. A., Schwartz, M. A., Krol, G., and Oberhansli, W., 1965, The metabolic fete of 14C-labeled chlordiazepoxide in men, in the dog and in the rat, J. Pharmacol. Exp. Ther.148:399.PubMedGoogle Scholar
  75. Kragh-Sorensen, P., Hansen, C. E., Baastrup, P. C., and Hvidberg, E. F., 1976, Self-inhibiting action of nortriptyline’s antidepressive effects at high plasma levels: A randomized, double-blind study controlled by plasma concentrations in patients with endogenous depression, Psychopharmacologia45:305–312.PubMedGoogle Scholar
  76. Kreuz, D. S., and Axelrod, J., 1974, Amphetamine in human plasma: A sensitive and specific enzymatic assay, Science183:420–421.PubMedGoogle Scholar
  77. Kuhn, R., 1958, The treatment of depressive states with G22355 (imipramine hydrochloride), Am. J. Psychiatry115:459–464.PubMedGoogle Scholar
  78. Levine, R. R., 1973, Pharmacology: Drug Actions and Reactions, Little, Brown and Co., Boston.Google Scholar
  79. Lewis, D. M., Curry, S. H., and Samuel, G., 1971, Long acting phenothiazines in schizophrenia, Br. Med. J.1:671–672.PubMedGoogle Scholar
  80. Macfie, A. C., 1975, Lithium poisoning precipitated by diuretics, Br. Med. J.1:516.PubMedGoogle Scholar
  81. MacKay, A. V. P., Healey, A. F., and Baker, J., 1974, The relationship of plasma chlorpromazine to its 7-hydroxy and sulfoxide metabolites in a large population of chronic schizophrenics, Br. J. Clin. Pharmacol.1:425–429.PubMedGoogle Scholar
  82. Manian, A. A., Piette, L. H., Holland, D., Grover, T., and Leterrier, F., 1974, Red blood cell drug binding as a possible mechanism for tranquilezation, in: The Phenothiazines and Structurally Related Drugs (I. S. Forrest, C.J. Carr, and E. Usdin, eds.), pp. 149–161 Raven Press, New York.Google Scholar
  83. McKnelly, W. V., Jr., Tupin, J., and Dunn, M., 1970, Lithium in hazardous circumstances with one case of lithium toxicity, Comp. Psychiatry11:279.Google Scholar
  84. Morselli, P. L., Cassano, G. B., Placidi, G. F., Muscettola, G. B., and Rizzo, M., 1973, Kinetics of distribution of 14C-diazepam and its metabolites in various areas of the cat brain, in: The Benzodiazepines (S. Garattini, E. Mussini, and O. H. Randall, eds.), pp. 129–143, Raven Press, New York.Google Scholar
  85. Notare, R. E., 1975, Biopharmaceutics and Pharmacokinetics, An Introduction, 2nd Ed., Marcel Dekker, Inc., New York.Google Scholar
  86. Post, R. M., and Goodwin, F., 1974, Effects of amitriptyline and imipramine on amine metabolites in the cerebrospinal fluid of depressed patients, Arch. Gen. Psychiatry30:234–239.PubMedGoogle Scholar
  87. Prien, R. F., Caffey, E. M., and Klett, D. J., 1971, The relationship between serum lithium level and clinical response in acute mania treated with lithium carbonate cooperative studies in psychiatry, Prepublication Report No. 91, Veterans Administration, National Institute of Mental Health Collaborative Study Group, Washington, D.C.Google Scholar
  88. Rivera-Calimlim, L., Castanneda, L., and Lasagna, L., 1973, Effects of mode of management on plasma chlorpromazine in psychiatric patients, Clin. Pharmacol. Ther.14:978–986.PubMedGoogle Scholar
  89. Sakalis, G., Curry, S. H., Mould, G. P., and Lader, M. H., 1972, Physiologic and clinical effects of chlorpromazine and their relationship to plasma level, Clin. Pharmacol. Ther.13:931–946.PubMedGoogle Scholar
  90. Sakalis, G., Chan, T. L., Gershon, S., and Park, S., 1973, The possible role of metabolites in therapeutic response to chlorpromazine treatment, Psychopharmacologica32:279–284.Google Scholar
  91. Sakurai, Y., Nakahara, T., and Takahashi, R., 1975, Prediction of response to chlorpromazine treatment in schizophrenics, Psychopharmacologia44:195–203.PubMedGoogle Scholar
  92. Schooler, N. R., Sakalis, G., Chan, T. L., Gershon, S., Goldber, S. C., and Collins, P., 1976, Chlorpromazine metabolism and clinical response in acute schizophrenia: A preliminary report, in: Pharmacokinetics of Psychoactive Drugs (L. A. Gottschalk and S. Merlis, eds.), pp. 199–219, Spectrum Publications, New York.Google Scholar
  93. Schou, M., 1958, Lithium studies. Distribution between serum and tissues, Acta Pharmacol. Toxicol.15:115.Google Scholar
  94. Schou, M., 1968, Lithium in psychiatry. A review in psychopharmacology: A review of progress 1957–1967, PHS Publication No. 1886, p. 701, U.S. Government Printing Office, Washington, D.C.Google Scholar
  95. Schou, M., 1969, Lithium: Relation between clinical effects of the drug and its absorption, distribution and excretion in: The Present Status of Psychotropic Drugs (A. Cerletti and F. J. Bové, eds.), pp. 120–122, Excerpta Medica, Amsterdam.Google Scholar
  96. Schou, M., and Amdisen, A., 1973, Lithium and pregnancy. III. Lithium ingestion by children breast-fed by women on lithium treatment, Br. Med. J.2:138.PubMedGoogle Scholar
  97. Schou, M., Amdisen, A., and Baastrup, P. C., 1971, The practical management of lithium treatment, Br. J. Hosp. Med.6:53.Google Scholar
  98. Schou, M., Amdisen, A., and Stefenstrup, O. R., 1973, Lithium and pregnancy. II. Hazards to women given lithium during pregnancy and delivery, Br. Med. J.2:137–138.PubMedGoogle Scholar
  99. Schwartz, M. A., and Postma, E., 1966, Metabolic demethylation of chlordiazepoxide, J. Pharm. Sci.55:1358–1362.Google Scholar
  100. Schwartz, M. A., Koechlin, B. A., Postma, E., and Krol, G., 1965, Metabolism of diazepam in rat, dog and man, J. Pharmacol. Exp. Ther.149:423–435.PubMedGoogle Scholar
  101. Sjoqvist, J., Hammer, W., Idestrom, C. M., Lind, M., Tuck, D., and Asberg, M., 1968, Plasma levels of monomethylated tricyclic antidepressants and side effects in man, Excerpta Med. Int. Congr. Ser.145:246–257.Google Scholar
  102. Tuck, J. R., and Punell, G., 1973, Uptake of [3H]-5-hydroxytryptamine and [3H]-noradrenaline by slices of rat brain incubated with chlorimipramine, imipramine and amitripty-line, J. Pharm. Pharmacol.25:573–574.PubMedGoogle Scholar
  103. Turner, W. J., Turano, P., and Badzinski, S., 1976, An attempt to establish quality control in determination of plasma chlorpromazine by a multi-laboratory collaboration, in: Pharmacokinetics of Psychoactive Drugs (L. A. L. Gottschalk and S. Merlis, eds.), pp. 33–43, Spectrum Publications, New York.Google Scholar
  104. Von Bahr, C., and Orrenius, S., 1971, Spectral studies on the interactions of imipramine and some of its oxidized metabolites with rat liver microsomes, Xenobiotica1:69–78.Google Scholar
  105. Vree, T. B., Muskens, A. T. J. M., and Van Rossum, J. M., 1972, Excretion of amphetamines in human sweat, Arch. Int. Pharmacodyn. Ther.199:311–317.PubMedGoogle Scholar
  106. Warick, L. H., 1966, Lithium salts in treatment of manic states, Dis. Nerv. Syst.27:527.PubMedGoogle Scholar
  107. Watanabe, S., Taguchi, K., Ebara, T., Iguchi, K., and Otsuki, S., 1973, Lithium concentration in cerebrospinal fluid of affective psychotic patients treated with lithium carbonate and its clinical response, Folia Psychiatr. Neurol. Jpn.27:299–303.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1978

Authors and Affiliations

  • D. R. Britton
    • 1
  • Z. S. El-Wardany
    • 1
  • C. P. Brown
    • 1
  • J. R. Bianchine
    • 1
  1. 1.Departments of Pharmacology and MedicineThe Ohio State University College of MedicineColumbusUSA

Personalised recommendations